|
|
|
| Network pharmacological study on the mechanism of action of Atractylodis Macrocephalae Rhizoma and Atractylodis Rhizoma couplet medicines on the intervention of ulcerative colitis |
| DAI Mingming1 LIAO Dan2 CHENG Weiling1 WANG Chunpeng1 LIN Caizhi3 |
1.Graduate School, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530000, China;
2.School of Basic Medicine, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530000, China;
3.Department of Spleen, Stomach and Liver Diseases, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530000, China |
|
|
|
Abstract Objective To analyze the mechanism of action of Atractylodis Macrocephalae Rhizoma and Atractylodis Rhizoma couplet medicines on the intervention of ulcerative colitis (UC) based on network pharmacology. Methods The active components and target genes of Atractylodis Macrocephalae Rhizoma and Atractylodis Rhizoma were screened by traditional Chinese medicine systems pharmacology database and analysis platform and bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine. UC-related genes were obtained using GeneCards, a human gene database. Cytoscape software was used to build the “drug-active component-target-disease” network. Proteinprotein interaction network diagrams of Atractylodis Macrocephalae Rhizoma and Atractylodis Rhizoma couplet medicines on disease targets were constructed by String database. GO functional enrichment and KEGG pathway enrichment analysis of key target genes were performed using R language software. Results A total of 16 active ingredients were screened out. A total of 4209 UC-related genes were retrieved. A total of 31 common targets of couplet medicines and disease-related were screened out. The main core genes included E1A binding protein P300, tumor necrosis factor-α, mitogen-activated protein kinase 1 (MAPK1), etc. The main signaling pathways included phosphoinositol-3 kinase/protein kinase B, nuclear factor-κB, human T-cell leukemia virus type 1, MAPK, hypoxia-inducible factor-1, etc. Conclusion By building a “drug-active component-target-disease” network, from multiple components, multiple targets, multiple pathways to interpret mechanism of action of Atractylodis Macrocephalae Rhizoma and Atractylodis Rhizoma couplet medicines to intervene in the UC, provide the basis for subsequent research and reference.
|
|
|
|
|
|
[1] 李军祥，陈誩.溃疡性结肠炎中西医结合诊疗共识意见（2017年）[J].中国中西医结合消化杂志，2018，26（2）：105-111，120.
[2] 雷娜，孔鹏飞，陈思敏，等.槐花散合桃花汤加减对溃疡性结肠炎活动期寒热错杂证免疫炎症的调节作用[J].中国实验方剂学杂志，2020，26（7）：86-91.
[3] Conrad K，Roggenbuck D，Laass MW. Diagnosis and classification of ulcerative colitis [J]. Autoimmunity Rev，2014，13（4/5）：463-466.
[4] 吴萍建.柴芍六君汤治疗肝郁脾虚型溃疡性结肠炎的疗效观察[D].广州：广州中医药大学，2018.
[5] 郭玲珑，姜小艳，李娟娟，等.溃疡性结肠炎的中医药治疗研究进展[J].中国当代医药，2020，27（34）：26-30.
[6] 陈锋，严常开.治疗溃疡性结肠炎药物的最新进展[J].世界华人消化杂志，2016，24（12）：1840-1845.
[7] 张声生，赵鲁卿.溃疡性结肠炎的中医治疗策略和思考[J].中国中西医结合消化杂志，2016，24（6）：411-413.
[8] Cai H，Xu Y，Xie L，et al. Investigation on Spectrum-Effect Correlation between Constituents Absorbed into Blood and Bioactivities of Baizhu Shaoyao San before and after Processing on Ulcerative Colitis Rats by UHPLC/Q-TOF-MS/MS Coupled with Gray Correlation Analysis [J]. Molecules，2019，24（5）：940.
[9] Dong H，He L，Huang M，et al. Anti-inflammatory components isolated from Atractylodes macrocephala Koidz [J]. Nat Prod Res，2008，22（16）：1418-1427.
[10] 朱慧敏，朱杭溢，陈武，等.白术水提物对溃疡性结肠炎大鼠炎性因子的影响[J].浙江中医杂志，2014，49（1）：51-53.
[11] 刘苗，申睿，谈望晶，等.中医药治疗溃疡性结肠炎研究进展[J].西部中医药，2019，32（5）：139-142.
[12] Lu C，Fu W，Zhou R，et al. Network pharmacology-based study on the mechanism of Yiganling capsule in hepatitis B treatment [J]. BMC Complement Med Ther，2020，20（1）：37.
[13] Ahmadi Ghezeldasht S，Shirdel A，Assarehzadegan MA，et al. Human T Lymphotropic Virus Type Ⅰ（HTLV-Ⅰ）Oncogenesis：Molecular Aspects of Virus and Host Interactions in Pathogenesis of Adult T cell Leukemia/Lymphoma（ATL）[J]. Iran J Basic Med Sci，2013，16（3）：179-195.
[14] León J，Casado J，Jiménez Ruiz SM，et al. Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-κβ [J]. J Pineal Res，2014，56（4）：415-426.
[15] 王其进，陈玉，张涛，等.FOXO3调控NF-κBp50表达介导肠上皮细胞凋亡参与溃疡性结肠炎相关癌变及健脾清热活血方药干预研究[J].时珍国医国药，2015，26（12）：3043-3046.
[16] Lu PD，Zhao YH. Targeting NF-κB pathway for treating ulcerative colitis：comprehensive regulatory characteristics of Chinese medicines [J]. Chin Med，2020，15：15.
[17] 张涛，黄会云，曹火留，等.PI3K-Akt/mTOR通路调控P-β-catenin介导溃疡性结肠炎相关癌变及健脾清热活血方防治研究[J].时珍国医国药，2013，24（8）：2039-2041.
[18] 罗燕，陈志涛，徐崇明，等.VSL#3通过PI3K/Akt信号通路调节溃疡性结肠炎大鼠调节性T细胞表达[J].华中科技大学学报：医学版，2019，48（4）：411-416.
[19] Larmonier CB，Midura-Kiela MT，Ramalingam R，et al. Modulation of neutrophil motility by curcumin：implications for inflammatory bowel disease [J]. Inflamm Bowel Dis，2011，17（2）：503-515.
[20] 赵海梅，黄敏芳，刘端勇，等.黄芪多糖对急性溃疡性结肠炎大鼠结肠黏膜PI3K/Akt信号的调控作用[J].中成药，2015，37（9）：2029-2031.
[21] Twait E，Williard D，Samuel I. Crosstalk Between NF-κB and AP-1 Nuclear Transcription Factor Pathways May Exacerbate Acute Pancreatic Inflammation [J]. Gastroenterology，2011，140（5）：S386-S387.
[22] Ma H，Zhou M，Duan W，et al. Anemoside B4 prevents acute ulcerative colitis through inhibiting of TLR4/NF-κB/MAPK signaling pathway [J]. Int Immunopharmacol，2020，87：106794.
[23] Gayther SA，Batley SJ，Linger L，et al. Mutations truncating the EP300 acetylase in human cancers [J]. Nat Genet，2000，24（3）：300-303.
[24] Kowalczyk AE，Krazinski BE，Godlewski J，et al. Expression of the EP300，TP53 and BAX genes in colorectal cancer：Correlations with clinicopathological parameters and survival [J]. Oncol Rep，2017，38（1）：201-210.
[25] Song Y，Kim YR，Kim SM，et al. RNAi-mediated silencing of TNF-α converting enzyme to down-regulate soluble TNF-α production for treatment of acute and chronic colitis [J]. J Control Release，2016，239：231-241.
[26] 李毅，刘艳，许永攀，等.康复新液联合美沙拉嗪治疗溃疡性结肠炎的疗效及对血清炎性因子和T淋巴细胞亚群水平的影响[J].华西药学杂志，2017，32（1）：111-112.
[27] 段婷娜，刘芳.美沙拉秦灌肠液联合双歧杆菌三联活菌肠溶胶囊治疗溃疡性结肠炎的临床效果及对患者炎症因子水平的影响[J].中国医药，2021，16（4）：579-582.
[28] Xiao B，Chen Q，Zhang Z，et al. TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis [J]. J Control Release，2018，287：235-246.
[29] 何晓瑞.溃疡性结肠炎的发病机制和药物治疗的研究进展[J].中国当代医药，2018，25（7）：25-27. |
|
|
|
